LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

Search

Cara Therapeutics Inc

Cerrado

Sector Salud

4.99 -0.8

Resumen

Variación precio

24h

Actual

Mínimo

4.99

Máximo

5.16

Métricas clave

By Trading Economics

Ingresos

-12M

Ventas

1.6M

2.6M

BPA

-0.118

Margen de beneficio

-488.106

Empleados

55

EBITDA

4.2M

-10M

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-23M

22M

Apertura anterior

5.79

Cierre anterior

4.99

Noticias sobre sentimiento de mercado

By Acuity

63%

37%

347 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Cara Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 mar 2025, 22:30 UTC

Adquisiciones, fusiones, absorciones

Toyota Tsusho Unit to Buy Radius Recycling for $30 a Share -- Update

13 mar 2025, 21:39 UTC

Adquisiciones, fusiones, absorciones

Toyota Tsusho to Buy Radius Recycling

13 mar 2025, 23:57 UTC

Charlas de Mercado

Better Gold, Iron Ore Outlook Boosts Australian Miners' Fortunes -- Market Talk

13 mar 2025, 23:55 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

13 mar 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

13 mar 2025, 23:30 UTC

Charlas de Mercado

Scope for US Share Market Reversal To Extend Further -- Market Talk

13 mar 2025, 23:06 UTC

Principales Noticias

Democrats Clear Way for GOP Bill, Ending Threat of Shutdown -- 3rd Update

13 mar 2025, 22:36 UTC

Adquisiciones, fusiones, absorciones

Buffett Hates Selling Anything. The Sale of Berkshire's Real Estate Unit Would Be Unusual. -- Barrons.com

13 mar 2025, 22:24 UTC

Adquisiciones, fusiones, absorciones

Buffett Hates Selling Anything. The Sale of Its Real Estate Unit Would Be Unusual. -- Barrons.com

13 mar 2025, 21:35 UTC

Charlas de Mercado

Australian Stocks Set to Open Lower After More U.S. Losses -- Market Talk

13 mar 2025, 21:35 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

13 mar 2025, 21:32 UTC

Principales Noticias
Ganancias
Adquisiciones, fusiones, absorciones

Compass in Talks to Buy Warren Buffett's Real-Estate Brokerage Unit -- Update

13 mar 2025, 21:08 UTC

Ganancias

Wheaton Precious Metals 4Q Adj EPS 43c >WPM

13 mar 2025, 21:08 UTC

Ganancias

Wheaton Precious Metals 4Q EPS 19c >WPM

13 mar 2025, 21:08 UTC

Ganancias

Wheaton Precious Metals 4Q Sales $380.5M >WPM

13 mar 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Radius Recycling: Implied Total Enterprise Value of Deal, Including Net Debt, Is About $1.34 B >RDUS

13 mar 2025, 21:03 UTC

Adquisiciones, fusiones, absorciones

Radius Recycling Expects to Benefit From TTC's Strong Relationships With Automotive OEMs and Tier 1, 2, and 3 Suppliers >RDUS

13 mar 2025, 21:03 UTC

Adquisiciones, fusiones, absorciones

Radius Recycling Says Teams, Operating Facilities, Strategy, and Brands Will Be Retained >RDUS

13 mar 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

Radius Recycling Will Continue to Operate From Current Headquarters in Portland, Oregon >RDUS

13 mar 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

Radius Recycling Shareholders to Receive $30 in Cash Per Shr >RDUS

13 mar 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

RADIUS RECYCLING to Be Acquired by U.S. Subsidiary of TOYOTA TSUSHO >RDUS

13 mar 2025, 21:00 UTC

Adquisiciones, fusiones, absorciones

RADIUS RECYCLING To Be Acquired By U.S. Subsidiary Of TOYOTA TSUSHO CORPORATION (TTC), Accelerating Investment In Future Growth >RDUS

13 mar 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

13 mar 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 mar 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

13 mar 2025, 20:37 UTC

Principales Noticias

Trump Ramps Up EU Trade War With Tariff Threat on Champagne, Wine -- Update

13 mar 2025, 20:34 UTC

Charlas de Mercado

U.S. Tariffs May Slow Down Mexico's Nearshoring -- Market Talk

13 mar 2025, 20:30 UTC

Principales Noticias

S&P 500 Suffers Correction After Trump Threatens Europe With More Tariffs -- WSJ

13 mar 2025, 20:29 UTC

Adquisiciones, fusiones, absorciones

Compass in Talks to Buy Warren Buffett's Real-Estate Brokerage Unit -- WSJ

13 mar 2025, 20:28 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

Comparación entre iguales

Cambio de precio

Cara Therapeutics Inc Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.835 / 5.125Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

347 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cara Therapeutics Inc

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.